ProfileGDS5678 / 1426638_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 39% 39% 41% 47% 40% 40% 38% 36% 39% 50% 38% 40% 37% 38% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9384739
GSM967853U87-EV human glioblastoma xenograft - Control 22.8946539
GSM967854U87-EV human glioblastoma xenograft - Control 32.93941
GSM967855U87-EV human glioblastoma xenograft - Control 43.0367447
GSM967856U87-EV human glioblastoma xenograft - Control 52.862240
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0034340
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9171238
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8207736
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8750939
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1789850
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8663538
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8785740
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.855637
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8580638